Lipoprotein(a) and risk of sudden cardiac death in middle-aged Finnish men: A new prospective cohort study

International Journal of Cardiology

Volumn 220, Issue , 2016, Pages 718-725

  Kunutsor, Setor K ^a   Khan, Hassan ^b   Nyyssönen, Kristiina ^c   Laukkanen, Jari A ^c,d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Central Finland Central Hospital   (Finland)

Author keywords

Lipoprotein(a); Risk factor; Risk prediction; Sudden cardiac death

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FINN (CITIZEN); HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RESTING HEART RATE; SMOKING; SUDDEN CARDIAC DEATH; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DEATH, SUDDEN, CARDIAC; FINLAND; FOLLOW UP; HEART DISEASES; RISK FACTOR;

ADULT; BIOMARKERS; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; FINLAND; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84977652445     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.069     Document Type: Article

References (57)

1. [1] Dube, J.B., Boffa, M.B., Hegele, R.A., Koschinsky, M.L., Lipoprotein(a): more interesting than ever after 50 years. Curr. Opin. Lipidol. 23 (2012), 133–140.
2. [2] Emerging Risk Factors C, Erqou, S., Kaptoge, S., Perry, P.L., Di Angelantonio, E., Thompson, A., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 (2009), 412–423.
3. [3] Clarke, R., Peden, J.F., Hopewell, J.C., Kyriakou, T., Goel, A., Heath, S.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361 (2009), 2518–2528.
4. [4] Kamstrup, P.R., Tybjaerg-Hansen, A., Steffensen, R., Nordestgaard, B.G., Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301 (2009), 2331–2339.
5. [5] Kamstrup, P.R., Nordestgaard, B.G., Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart Fail. 4 (2016), 78–87.
6. [6] Tsimikas, S., Hall, J.L., Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol. 60 (2012), 716–721.
7. [7] Gillum, R.F., Geographic variation in sudden coronary death. Am. Heart J. 119 (1990), 380–389.
8. [8] Hayashi, M., Shimizu, W., Albert, C.M., The spectrum of epidemiology underlying sudden cardiac death. Circ. Res. 116 (2015), 1887–1906.
9. [9] Dudas, K., Lappas, G., Stewart, S., Rosengren, A., Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation 123 (2011), 46–52.
10. [10] Gerber, Y., Jacobsen, S.J., Frye, R.L., Weston, S.A., Killian, J.M., Roger, V.L., Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation 113 (2006), 2285–2292.
11. [11] Deo, R., Albert, C.M., Epidemiology and genetics of sudden cardiac death. Circulation 125 (2012), 620–637.
12. [12] Albert, C.M., Ma, J., Rifai, N., Stampfer, M.J., Ridker, P.M., Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 105 (2002), 2595–2599.
13. [13] Grundy, S.M., D'Agostino, R.B. Sr., Mosca, L., Burke, G.L., Wilson, P.W., Rader, D.J., et al. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, lung, and blood institute workshop. Circulation 104 (2001), 491–496.
14. [14] Spooner, P.M., Zipes, D.P., Sudden death predictors: an inflammatory association. Circulation 105 (2002), 2574–2576.
15. [15] von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke, J.P., The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 61 (2008), 344–349.
16. [16] Karppi, J., Kurl, S., Makikallio, T.H., Ronkainen, K., Laukkanen, J.A., Serum beta-carotene concentrations and the risk of congestive heart failure in men: a population-based study. Int. J. Cardiol. 168 (2013), 1841–1846.
17. [17] Laukkanen, J.A., Makikallio, T.H., Rauramaa, R., Kiviniemi, V., Ronkainen, K., Kurl, S., Cardiorespiratory fitness is related to the risk of sudden cardiac death: a population-based follow-up study. J. Am. Coll. Cardiol. 56 (2010), 1476–1483.
18. [18] Salonen, J.T., Nyyssonen, K., Korpela, H., Tuomilehto, J., Seppanen, R., Salonen, R., High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86 (1992), 803–811.
19. [19] Kunutsor, S.K., Khan, H., Laukkanen, J.A., Gamma-glutamyltransferase and risk of sudden cardiac death in middle-aged Finnish men: a new prospective cohort study. J. Am. Heart Assoc., 5(2), Feb 8 2016, 10.1161/JAHA.115.002858 (pii: e002858).
20. [20] Salonen, J.T., Salonen, R., Seppanen, K., Rauramaa, R., Tuomilehto, J., HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 84 (1991), 129–139.
21. [21] Therneau, T.M., Grambsch, P.M., Modeling Survival Data: Extending the Cox Model. 2000, Springer, New York.
22. [22] MacMahon, S., Peto, R., Cutler, J., Collins, R., Sorlie, P., Neaton, J., et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335 (1990), 765–774.
23. [23] Fibrinogen Studies Collaboration, Wood, A.M., White, I., Thompson, S.G., Lewington, S., Danesh, J., Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int. J. Epidemiol. 35 (2006), 1570–1578.
24. [24] Rosner, B., Willett, W.C., Spiegelman, D., Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error. Stat. Med. 8 (1989), 1051–1069 (discussion 71-3).
25. [25] Harrell, F.E. Jr., Lee, K.L., Mark, D.B., Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15 (1996), 361–387.
26. [26] Pencina, M.J., D'Agostino, R.B. Sr., Steyerberg, E.W., Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat. Med. 30 (2011), 11–21.
27. [27] Kunutsor, S.K., Kurl, S., Zaccardi, F., Laukkanen, J.A., Baseline and long-term fibrinogen levels and risk of sudden cardiac death: a new prospective study and meta-analysis. Atherosclerosis 245 (2016), 171–180.
28. [28] Bennet, A., Di Angelantonio, E., Erqou, S., Eiriksdottir, G., Sigurdsson, G., Woodward, M., et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch. Intern. Med. 168 (2008), 598–608.
29. [29] Kronenberg, F., Kronenberg, M.F., Kiechl, S., Trenkwalder, E., Santer, P., Oberhollenzer, F., et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100 (1999), 1154–1160.
30. [30] Nave, A.H., Lange, K.S., Leonards, C.O., Siegerink, B., Doehner, W., Landmesser, U., et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis 242 (2015), 496–503.
31. [31] Arsenault, B.J., Boekholdt, S.M., Dube, M.P., Rheaume, E., Wareham, N.J., Khaw, K.T., et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case–control cohort. Circ. Cardiovasc. Genet. 7 (2014), 304–310.
32. [32] Nielsen, L.B., Gronholdt, M.L., Schroeder, T.V., Stender, S., Nordestgaard, B.G., In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler. Thromb. Vasc. Biol. 17 (1997), 905–911.
33. [33] Franzini, M., Corti, A., Martinelli, B., Del Corso, A., Emdin, M., Parenti, G.F., et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques — biochemical similarities with the circulating enzyme. Atherosclerosis 202 (2009), 119–127.
34. [34] Paolicchi, A., Emdin, M., Ghliozeni, E., Ciancia, E., Passino, C., Popoff, G., et al. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation, 109, 2004, 1440.
35. [35] Davies, M.J., Anatomic features in victims of sudden coronary death. Coronary artery pathology. Circulation 85 (1992), I19–I24.
36. [36] Deb, A., Caplice, N.M., Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin. Cardiol. 27 (2004), 258–264.
37. [37] Boffa, M.B., Marcovina, S.M., Koschinsky, M.L., Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin. Biochem. 37 (2004), 333–343.
38. [38] Tsimikas, S., Brilakis, E.S., Miller, E.R., McConnell, J.P., Lennon, R.J., Kornman, K.S., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353 (2005), 46–57.
39. [39] Davies, M.J., Thomas, A., Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N. Engl. J. Med. 310 (1984), 1137–1140.
40. [40] Insull, W. Jr., McGovern, M.E., Schrott, H., Thompson, P., Crouse, J.R., Zieve, F., et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch. Intern. Med. 164 (2004), 1121–1127.
41. [41] Merki, E., Graham, M.J., Mullick, A.E., Miller, E.R., Crooke, R.M., Pitas, R.E., et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118 (2008), 743–753.
42. [42] Kastelein, J.J., Wedel, M.K., Baker, B.F., Su, J., Bradley, J.D., Yu, R.Z., et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114 (2006), 1729–1735.
43. [43] Davey Smith, G., Ebrahim, S., ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?. Int. J. Epidemiol. 32 (2003), 1–22.
44. [44] Kronenberg, F., Utermann, G., Lipoprotein(a): resurrected by genetics. J. Intern. Med. 273 (2013), 6–30.
45. [45] Boerwinkle, E., Leffert, C.C., Lin, J., Lackner, C., Chiesa, G., Hobbs, H.H., Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90 (1992), 52–60.
46. [46] Group, H.T.C., Landray, M.J., Haynes, R., Hopewell, J.C., Parish, S., Aung, T., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371 (2014), 203–212.
47. [47] AIM-HIGH Investigators, Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365 (2011), 2255–2267.
48. [48] Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372 (2015), 1489–1499.
49. [49] Nordestgaard, B.G., Chapman, M.J., Ray, K., Boren, J., Andreotti, F., Watts, G.F., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31 (2010), 2844–2853.
50. [50] Davidson, M.H., Ballantyne, C.M., Jacobson, T.A., Bittner, V.A., Braun, L.T., Brown, A.S., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J. Clin. Lipidol. 5 (2011), 338–367.
51. [51] Grundy, S.M., National Cholesterol Education Program — the National Cholesterol Guidelines in ATP, III. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am. J. Cardiol. 90 (2002), 11i–21i.
52. [52] Tsimikas, S., Viney, N.J., Hughes, S.G., Singleton, W., Graham, M.J., Baker, B.F., et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386 (2015), 1472–1483.
53. [53] Jaeger, B.R., Richter, Y., Nagel, D., Heigl, F., Vogt, A., Roeseler, E., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat. Clin. Pract. Cardiovasc. Med. 6 (2009), 229–239.
54. [54] Leebmann, J., Roeseler, E., Julius, U., Heigl, F., Spitthoever, R., Heutling, D., et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128 (2013), 2567–2576.
55. [55] Atwater, B.D., Thompson, V.P., Vest, R.N. 3rd, Shaw, L.K., Mazzei, W.R. Jr., Al-Khatib, S.M., et al. Usefulness of the Duke sudden cardiac death risk score for predicting sudden cardiac death in patients with angiographic (> 75% narrowing) coronary artery disease. Am. J. Cardiol. 104 (2009), 1624–1630.
56. [56] Russo, A.M., Stainback, R.F., Bailey, S.R., Epstein, A.E., Heidenreich, P.A., Jessup, M., et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Heart Rhythm 10 (2013), e11–e58.
57. [57] Sandholzer, C., Hallman, D.M., Saha, N., Sigurdsson, G., Lackner, C., Csaszar, A., et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum. Genet. 86 (1991), 607–614.